Quantcast

Latest Janus kinase 2 Stories

2014-08-27 08:27:31

SAN DIEGO, Aug. 27, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Baird 2014 Health Care Conference to be held at The New York Palace Hotel in New York City on September 3-4, 2014. Alan Fuhrman, Ambit's CFO, will provide an overview of the Company and its lead drug candidate,...

2014-08-07 04:21:40

SEATTLE, Aug. 7, 2014 /PRNewswire/ --CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose...

2014-07-23 08:31:05

MILWAUKEE, July 23, 2014 /PRNewswire-USNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a Calreticulin (CALR) mutation analysis to identify gene mutations that are found in patients with rare and chronic blood disorders. Detecting a CALR mutation vastly improves the diagnosis of myeloproliferative neoplasms (MPN), a group of diseases that affect blood cell formation. Accurate diagnosis of these disorders provides physicians with...

2014-07-01 04:21:47

-Top-line Results Expected in Early 2015- SEATTLE, July 1, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI or the Company) (NASDAQ and MTA: CTIC) announced today that it has completed recruitment in the PERSIST-1 pivotal Phase 3 clinical trial of pacritinib, a novel oral JAK2/FLT3 inhibitor that is being evaluated for the treatment of myelofibrosis. Under the development and commercialization agreement for pacritinib with Baxter International, Inc. (Baxter), CTI expects to receive a...

2014-05-28 08:30:57

SAN DIEGO, May 28, 2014 /PRNewswire/ -- Ambit Biosciences (NASDAQ:AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Jefferies 2014 Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on June 2-5, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2014-05-01 08:35:41

SAN DIEGO, Calif., May 1, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Deutsche Bank 39(th) Annual Healthcare Conference to be held at the InterContinental Hotel in Boston, MA, May 7-8, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug...

2014-04-10 16:24:24

HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose researchers recently published the discovery in the New England Journal of...

2014-03-03 04:22:38

- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300...

2014-02-04 08:33:18

SAN DIEGO, Feb. 4, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the Leerink Global Healthcare Conference to be held at the Waldorf Astoria in New York City, February 12-13, 2014. Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate,...

2014-01-30 23:31:18

Following the discovery of the Calreticulin (CALR) mutation, which accounts for the majority of non JAK/MPL mutations in ET and MF patients, Dr. Robert Kralovics sits down with MPN Research Foundation to discuss the discovery. Chicago, IL (PRWEB) January 30, 2014 In December 2013, Dr. Robert Kralovics sat down to discuss the discovery of a genetic mutation that explains the majority of ET and MF for non-JAK and MPL patients. Click here to watch the video. During the late breaking abstract...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related